Taisho have entered in to an agreement with Chugai to co-market ED-71, an activated vitamin D derivative that Chugai is currently developing in Japan for the treatment of osteoporosis
Filed under: Nuclear Receptor | Tagged: agonist, Taisho, Chugai, Roche, Vitamin D, ED71, ED-71, Eldecalcitol
Name (required)
Mail (will not be published) (required)
Website
